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Dr Chadrick Denlinger (Charleston, SC). Dr Wald, I enjoyed
your presentation. This work represents yet another contribution
from you and your laboratory related to the chemokines and che-
mokine receptors in the development and progression of cancer.
The importance of BKT140 and other similar drugs will likely
continue to grow as these drugs approach the clinical realm.
Your presentation this morning also demonstrates the systemic ef-
ficacy of BKT140 in your xenograft studies.
Your presentation focused primarily on the specificity of
BKT140 as it affects the CXCR4 receptor. As 1 of your earlier
slides demonstrated, there are a number of different chemokine re-
ceptors that likely have multiple layers of redundancy related to
similar ligand binding but different receptors and overlapping in-
tracellular second messenger systems. In this study, you focused
exclusively on the small molecule inhibitors of CXCR4—did
you consider also using more specific molecular agents, such as
short hairpin loops or siRNAs, as a more specific target for the
CXCR4?
Dr Wald. I think that this is an important concern. Actually,
siRNA silencing is indeed a great option to demonstrate the spec-
ificity. We have had some trouble achieving good transfectants and
good silencing of CXCR4 with our cell lines. However, it is known
that BKT140 competes with the antibody we used in immunohis-
tochemistry assay for a binding site on the CXCR4 receptor. This
is the anti-CXCR4 12G5 clone. Therefore, I believe that we can
exclude downregulation of the BKT140. Furthermore, there has
been extensive work done with the molecule showing its specific-
ity for CXCR4; nonetheless, we cannot absolutely rule out other
possibilities, and, indeed, it is possible that some of the effectsThe Journal of Thoracic and Carof BKT140 might be related to other mechanisms, rather than
blocking of CXCR4.
Dr Denlinger. Similarly, all the cell lines used in the study ex-
pressed CXCR4. Have you found some NSCLC cell lines that do
not express CXCR4 that could be possibly used as negative con-
trols for similar studies?
DrWald. The lines we have screened have all had some expres-
sion of CXCR4. Furthermore, we observed that when implanted in
mice, many cells that do not express CXCR4 tend to upregulate the
receptor and express it in vivo.
Dr Denlinger. In previous work from your group, you indicated
that it is primarily the fibroblasts that release the CXCL12 that
bind to the CXCR4 receptor. In some of the studies presented to-
day, no fibroblasts were involved, yet BKT140 seemed to have
antiproliferative effects. How do you explain these results?
Dr Wald.Most of these cell lines used in our experiments also
express CXCL12 in vitro, so an autocrine loop is possible.
Another issue that I think is important to consider is that the
mechanism by which the drug acts in vitro and in vivo might not
be similar. It is reasonable to assume that when cells are trans-
planted in vivo, CXCR12 and CXCR4 probably regulate multiple
processes in the tumor microenvironment. Therefore, I am not cer-
tain whether the effect we see in vivo simply represents the inhib-
itory effect or the cytotoxic effect of the drug ex vivo. Furthermore,
I am not certain that all the cytotoxic effects of the drug in vitro are
absolutely dependent on blocking the autocrine loop. I believe that
this is the casewhen performing colony assay. In these assays, it has
been also shown that other CXCR4 inhibitors, such as AMD300,
can block colony formation. However, proliferation is only blocked
by BKT140, not by other small molecules that target CXCR4.diovascular Surgery c Volume 144, Number 5 1175
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